Cardiotoxicidad de los quimioterapéuticos tipo antraciclinas de la lista oficial de medicamentos de la Caja Costarricense del Seguro Social

Salas Segura, Juliana; Pérez Carvajal, José Ignacio.
Rev. costarric. cardiol ; 20(2): 44-47, dic. 2018. tab
Artículo en Español | LILACS | ID: biblio-990969

Documentos relacionados

  1. Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology.
  2. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
  3. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
  4. Role of mitochondria in doxorubicin-mediated cardiotoxicity: from molecular mechanisms to therapeutic strategies.
  5. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications.
  6. Preventing and Treating Anthracycline Cardiotoxicity: New Insights.
  7. PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity.
  8. Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: Current understanding and existing evidence.
  9. Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets.
  10. Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp-3 in anthracycline-induced cardiotoxicity.